05:08 AM EDT, 10/20/2025 (MT Newswires) -- Mesoblast (MESO) reported Sunday a 66% jump in Ryoncil gross sales to $21.9 million in fiscal Q2 compared with the previous quarter, driven by increased physician adoption and broader reimbursement from both commercial and government payers.

Revenue from cell therapy products rose to $20.6 million for the quarter ended Sept. 30, up from $12.9 million in the prior quarter.

The company said it also entered into agreements to issue up to $50 million in unsecured convertible notes at its discretion, pending shareholder approval, to reduce existing debt and support working capital.